Glasgow firm lands £2m to develop nebuliser technology
Nebu~Flow, a Glasgow-based medical technology company, has been awarded a £2m Scottish Enterprise grant to accelerate development and patient access to its patented nebuliser technology in the UK and globally.
The technology is designed to improve how people receive inhaled medicines, paving the way for the medicines of tomorrow and reducing pressure on healthcare systems.
The Scottish Enterprise funding follows a successful £4.7 million investment round in 2024. It will support product development, preparations for regulatory approval and partnerships with pharmaceutical and biotech companies as Nebu~Flow works towards bringing the technology to market.
Nebulisers are a common means of delivering essential medicines to the lungs for people with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. These conditions place a significant and growing burden on healthcare systems worldwide, costing the NHS in Scotland alone around £500 million each year to manage. While nebulisers have existed for more than a century, the technology itself has barely changed. This restricts the types of medicines people can receive by inhalation, preventing them from benefiting from some newer, more effective therapies. Nebu~Flow’s new device is designed to change that.
Its patented aerosol-formation technology enables precise control of droplet size and distribution, delivering medicines more gently and efficiently to the lungs. Early studies show the system can successfully deliver a much wider range of medicines than existing nebulisers, including hard-to-nebulise and fragile medicines such as emerging biologics and advanced therapeutics.
Andrea Cusack, Chief Executive Officer of Nebu~Flow, said: “This support from Scottish Enterprise is a huge moment for our team. It allows us to turn years of Scottish research and engineering into a real product that could make a genuine difference to patients’ lives. Our goal is simple: to help people get better, more effective medicines in a way that’s easier, safer and more comfortable for them.”